|Chemical and physical data|
|Molar mass||398.366 g·mol−1|
|3D model (JSmol)|
Diflomotecan (also known as BN80905) is a chemotherapeutic agent that is a topoisomerase inhibitor (Top1). It varies from other camptothecin based Top1 inhibitors like topotecan in having a 7-membered E-ring. The oxepan-2-one ring in the homocamptothecin analogues is more stable in plasma compared to the 6-membered lactone in camptothecin. Diflomotecan was the first homocamptothecin to enter clinical trials and is currently in phase I for treating patients with sensitive small cell lung cancer (SCLC).
- Bailly C (2003). "Homocamptothecins: potent topoisomerase I inhibitors and promising anticancer drugs". Critical Reviews in Oncology/Hematology. 45: 91–108. doi:10.1016/s1040-8428(02)00090-2.
- Kroep JR, Gelderblom H (2009). "Diflomotecan, a promising homocamptothecin for cancer therapy". Expert Opin Investig Drugs. 18: 69–75. doi:10.1517/13543780802571674.
- "Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC) - Full Text View - ClinicalTrials.gov". clinicaltrials.gov.